# Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer

> **NCT04142554** · PHASE1 · WITHDRAWN · sponsor: **UNC Lineberger Comprehensive Cancer Center**

## Conditions studied

- Breast Cancer
- Breast Neoplasms
- Triple Negative Breast Cancer
- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Parsaclisib

## Key facts

- **NCT ID:** NCT04142554
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-06-01
- **Primary completion:** 2020-09-07
- **Final completion:** 2020-09-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding withdrawn from funding source.
- **Last updated:** 2020-11-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04142554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04142554, "Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04142554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*